CIRCULATING LEVELS OF EPIRUBICIN CAUSE ENDOTHELIAL SENESCENCE WHILE COMPROMISING METABOLIC ACTIVITY AND VASCULAR FUNCTION

Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function

Anthracycline-based chemotherapy is a common treatment for cancer patients.Because it is delivered intravenously, endothelial cells are exposed first and to the highest concentrations, prior to diffusion to target cells.Not surprisingly, vascular dysfunction is a consequence of anthracycline therapy.While chemotherapy-induced endothelial damage at

read more